These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 17681958

  • 1. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.
    Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
    [Abstract] [Full Text] [Related]

  • 2. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K.
    J Am Coll Cardiol; 2007 Feb 20; 49(7):753-62. PubMed ID: 17306703
    [Abstract] [Full Text] [Related]

  • 3. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
    Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group.
    Circulation; 2008 Jan 29; 117(4):526-35. PubMed ID: 18195176
    [Abstract] [Full Text] [Related]

  • 4. Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.
    Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.
    Nephrology (Carlton); 2014 May 29; 19(5):266-74. PubMed ID: 24506498
    [Abstract] [Full Text] [Related]

  • 5. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial.
    McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Polu KR, Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB, RED-HF Committees and Investigators.
    Eur J Heart Fail; 2009 Aug 29; 11(8):795-801. PubMed ID: 19633103
    [Abstract] [Full Text] [Related]

  • 6. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C.
    J Intern Med; 2006 Dec 29; 260(6):577-85. PubMed ID: 17116009
    [Abstract] [Full Text] [Related]

  • 7. The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure.
    Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Anker SD, Knusel B, Sun Y, Wasserman SM, van Veldhuisen DJ.
    Eur J Heart Fail; 2009 Nov 29; 11(11):1071-7. PubMed ID: 19815661
    [Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K, ARANESP 20030232 Study Group.
    Curr Med Res Opin; 2009 Sep 29; 25(9):2109-20. PubMed ID: 19601709
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 29; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 10. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure.
    Kourea K, Parissis JT, Farmakis D, Paraskevaidis I, Panou F, Filippatos G, Kremastinos DT.
    Eur J Cardiovasc Prev Rehabil; 2008 Jun 29; 15(3):365-9. PubMed ID: 18525396
    [Abstract] [Full Text] [Related]

  • 11. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Jun 29; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 12. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
    Bajo MA, Pérez Fontán M, Remón C, Sánchez-Tomero JA, Lladós F, Selgas R.
    Nefrologia; 2009 Jun 29; 29(2):136-42. PubMed ID: 19396319
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar 29; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 14. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE, Lombraña A, Duarte P, Di Gennaro F.
    J Am Coll Cardiol; 2007 Oct 23; 50(17):1657-65. PubMed ID: 17950147
    [Abstract] [Full Text] [Related]

  • 15. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
    Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ.
    Nephrol Dial Transplant; 2004 Apr 23; 19(4):898-903. PubMed ID: 15031347
    [Abstract] [Full Text] [Related]

  • 16. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, Kremastinos DT.
    Am Heart J; 2008 Apr 23; 155(4):751.e1-7. PubMed ID: 18371487
    [Abstract] [Full Text] [Related]

  • 17. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.
    J Am Med Dir Assoc; 2012 Mar 23; 13(3):244-8. PubMed ID: 21450214
    [Abstract] [Full Text] [Related]

  • 18. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease.
    Agarwal A, Silver MR, Walczyk M, Liu W, Audhya P.
    J Am Med Dir Assoc; 2007 Feb 23; 8(2):83-90. PubMed ID: 17289537
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V, Belani CP, Gill AN, Bhatt M, Tomita D, Rossi G, Ben-Jacob A.
    Oncologist; 2007 Jun 23; 12(6):727-37. PubMed ID: 17602062
    [Abstract] [Full Text] [Related]

  • 20. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P.
    Oncologist; 2006 Apr 23; 11(4):409-17. PubMed ID: 16614237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.